# Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

> **NCT01536392** · PHASE3 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 76 (actual)

## Conditions studied

- Cancer of the Cervix

## Interventions

- **DRUG:** Granisetron
- **DRUG:** Ondansetron
- **BEHAVIORAL:** Questionnaires
- **BEHAVIORAL:** Study Drug Diary

## Key facts

- **NCT ID:** NCT01536392
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2019-10-03
- **Final completion:** 2019-10-03
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2021-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01536392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01536392, "Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01536392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*